| Title |
First-Line and Maintenance Therapy for Ovarian Cancer: Current Status and Future Directions
|
|---|---|
| Published in |
Drugs, May 2014
|
| DOI | 10.1007/s40265-014-0221-9 |
| Pubmed ID | |
| Authors |
Antonio González-Martín, Luisa Sánchez-Lorenzo, Raquel Bratos, Raúl Márquez, Luis Chiva |
| Abstract |
Paclitaxel and carboplatin combination chemotherapy has remained the standard of care in the frontline therapy of advanced epithelial ovarian carcinoma during the last decade. Maintenance chemotherapy or immunotherapy has not been proven to impact on overall survival and only one clinical trial that explored the administration of monthly paclitaxel for 1 year showed a benefit in terms of progression-free survival (PFS), but at the cost of maintained alopecia and increased peripheral neuropathy. This scenario may be changing with the incorporation of targeted therapy to the frontline therapy of ovarian cancer. In particular, anti-angiogenic therapy has been identified as the most promising targeted therapy, and the addition of bevacizumab to first-line chemotherapy followed by a maintenance period of bevacizumab in monotherapy has shown to prolong PFS. This was considered the proof of concept of the value of anti-angiogenic therapy in the frontline of ovarian cancer, and the results of two additional clinical trials with anti-angiogenic tyrosine-kinase inhibitors have shown results in the same direction. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 39 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 18% |
| Researcher | 6 | 15% |
| Student > Ph. D. Student | 5 | 13% |
| Student > Postgraduate | 3 | 8% |
| Student > Master | 3 | 8% |
| Other | 6 | 15% |
| Unknown | 9 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 36% |
| Biochemistry, Genetics and Molecular Biology | 6 | 15% |
| Agricultural and Biological Sciences | 3 | 8% |
| Economics, Econometrics and Finance | 2 | 5% |
| Nursing and Health Professions | 1 | 3% |
| Other | 3 | 8% |
| Unknown | 10 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 September 2014.
All research outputs
#15,306,466
of 22,764,165 outputs
Outputs from Drugs
#2,792
of 3,251 outputs
Outputs of similar age
#132,656
of 226,270 outputs
Outputs of similar age from Drugs
#31
of 36 outputs
Altmetric has tracked 22,764,165 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,251 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,270 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.